
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 2)*

Neumora Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value \$0.0001 per share

(Title of Class of Securities)

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
 Rule 13d-1(c)
 Rule 13d-1(d)

SCHEDULE 13G

CUSIP No.

Names of Reporting Persons

1 K2 HealthVentures Equity Trust LLC

Check the appropriate box if a member of a Group (see instructions)

- 2 (a)
 (b)

3 Sec Use Only

Citizenship or Place of Organization

4 DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With: 5 Sole Voting Power
 0.00
 Shared Voting Power
 6
 5,790,453.00
 Sole Dispositive Power
 7
 0.00
 Shared Dispositive Power
 8
 5,790,453.00

9 Aggregate Amount Beneficially Owned by Each Reporting Person
 5,790,453.00
 10 Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

 11 Percent of class represented by amount in row (9)
 3.1 %
 12 Type of Reporting Person (See Instructions)
 OO

SCHEDULE 13G

CUSIP No.

1 Names of Reporting Persons
 Parag Shah
 Check the appropriate box if a member of a Group (see instructions)
 2 (a)
 (b)

3 Sec Use Only
 4 Citizenship or Place of Organization

UNITED STATES
 Sole Voting Power
 5
 0.00
 Shared Voting Power
 6
 5,790,453.00
 Sole Dispositive Power
 7
 0.00
 Shared Dispositive Power
 8
 5,790,453.00

9 Aggregate Amount Beneficially Owned by Each Reporting Person
 5,790,453.00
 10 Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11 Percent of class represented by amount in row (9)

3.1 %

Type of Reporting Person (See Instructions)

12

IN, HC

SCHEDULE 13G

CUSIP No.

Names of Reporting Persons

1

Anup Arora

Check the appropriate box if a member of a Group (see instructions)

2

(a)

(b)

3

Sec Use Only

Citizenship or Place of Organization

4

UNITED STATES

Sole Voting Power

5

0.00

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person
With:

Shared Voting Power

6

5,790,453.00

Sole Dispositive Power

7

0.00

Shared Dispositive

8

Power

5,790,453.00

Aggregate Amount Beneficially Owned by Each Reporting Person

9

5,790,453.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10

Percent of class represented by amount in row (9)

11

3.1 %

Type of Reporting Person (See Instructions)

12

IN, HC

SCHEDULE 13G

Item 1.

Name of issuer:

(a)

Neumora Therapeutics, Inc.

Address of issuer's principal executive offices:

(b)

260 Arsenal Place, Suite 1, Watertown, Massachusetts, 02472

Item 2.

Name of person filing:

(a) This Statement is filed on behalf of each of the following persons (collectively, the "Reporting Persons"): i. K2 HealthVentures Equity Trust LLC ("K2HV Equity"); ii. Parag Shah ("Mr. Shah"); and iii. Anup Arora ("Mr. Arora"). This Statement on Schedule 13G relates to an aggregate 5,790,453 shares of Common Stock K2HV Equity has the right to acquire within 60 days upon conversion of the remaining balance of the Issuer's outstanding debt obligations to K2HV Equity under the Loan and Security Agreement, dated as of May 9, 2025, between the Issuer and K2HV Equity, as amended by the First Amendment to Loan and Security Agreement, dated as of November 4, 2025, including (i) 4,558,926 shares of Common Stock that are issuable at a conversion price of the lesser of \$0.8774 per share and the lowest effective price per share of the Issuer's next equity financing (the "Original Conversion Shares"), and (ii) 1,231,527 shares of Common Stock that are issuable at a conversion price of \$2.03 per share, which is, as of the date of this Statement on Schedule 13G, the lesser of (a) \$2.3906 per share and (b) the lowest effective price per share in the Issuer's equity financing in Q1 2026 (the "Amendment Conversion Shares" and, together with the Original Conversion Shares, the "Conversion Shares"). For purposes of this Schedule 13G, we have assumed a conversion price of \$0.8774 per share for the Original Conversion Shares and \$2.03 for the Amendment Conversion Shares. K2HV Equity is an investment vehicle for holding equity securities and may be deemed to directly beneficially own the shares of Common Stock that it has the right to acquire upon conversion of the Conversion Shares, as reported herein. Mr. Shah and Mr. Arora serve as the managing members of K2HV Equity and, in such capacities, may be deemed to indirectly beneficially own the shares of Common Stock that K2HV Equity directly beneficially owns.

(b) Address or principal business office or, if none, residence:

The business address of each of the Reporting Persons is: 855 Boylston Street, 10th Floor, Boston, MA 02116.
Citizenship:

(c) K2HV Equity is a Delaware limited liability company. Each of Mr. Shah and Mr. Arora is a citizen of the United States of America.

(d) Title of class of securities:

Common Stock, par value \$0.0001 per share

(e) CUSIP No.:

Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

- (a) Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
- (b) Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
- (c) Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
- (d) Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
- (e) An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
- (f) An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
- (g) A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
- (h) A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- (i) A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
- (j) A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
- (k) Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

Item 4. Ownership

Amount beneficially owned:

(a) As of March 31, 2026, each of the Reporting Persons may be deemed the beneficial owner of 5,790,453 shares of Common Stock. This amount consists of an aggregate 5,790,453 shares of Common Stock K2HV Equity has the right to acquire upon conversion of the Conversion Shares.

(b) Percent of class:

As of March 31, 2026, each of the Reporting Persons may be deemed the beneficial owner of approximately 3.1% of the shares of Common Stock outstanding. The percentage set forth herein is calculated based on the sum of (i) 182,157,466 shares of Common Stock outstanding as of March 31, 2026, as reported in the Issuer's quarterly report on Form 10-Q, filed with the Securities and Exchange Commission on May 7, 2026, and (ii) an aggregate 5,790,453 shares of Common Stock that are issuable to K2HV Equity within 60 days upon conversion of the Conversion Shares,

which Conversion Shares have been added to the total shares of Common Stock outstanding in accordance with Rule 13d-3(d)(1)(i) under the Securities Exchange Act of 1934, as amended. %

(c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

0

(ii) Shared power to vote or to direct the vote:

5,790,453

(iii) Sole power to dispose or to direct the disposition of:

0

(iv) Shared power to dispose or to direct the disposition of:

5,790,453

Item 5. Ownership of 5 Percent or Less of a Class.

Ownership of 5 percent or less of a class

Item 6. Ownership of more than 5 Percent on Behalf of Another Person.

Not Applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable

Item 8. Identification and Classification of Members of the Group.

Not Applicable

Item 9. Notice of Dissolution of Group.

Not Applicable

Item 10. Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

K2 HealthVentures Equity Trust LLC

Signature: /s/ Anup Arora

Name/Title: Anup Arora, Managing Member

Date: 05/15/2026

Parag Shah

Signature: /s/ Parag Shah

Name/Title: Parag Shah

Date: 05/15/2026

Anup Arora

Signature: /s/ Anup Arora

Name/Title: Anup Arora

Date: 05/15/2026